Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring.
Dunn DT, Goodall RL, Munderi P, Kityo C, Ranopa M, Bacheler L, Van Houtte M, Gilks C, Kaleebu P, Pillay D; DART Virology and Trial Team. Dunn DT, et al. Among authors: bacheler l. Antimicrob Agents Chemother. 2011 Oct;55(10):4575-80. doi: 10.1128/AAC.00580-11. Epub 2011 Jul 18. Antimicrob Agents Chemother. 2011. PMID: 21768516 Free PMC article. Clinical Trial.
A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial.
Green H, Gibb DM, Compagnucci A, Giacomet V, de Rossi A, Harper L, Saïdi Y, Castelli-Gattinara G, Pillay D, Babiker AG, Aboulker JP, Lyall H, Bacheler LT, Walker AS, Debré M, Rosso R, Burger DM, Della Negra M, Dunn DT, Giaquinto C; Paediatric European Network for the Treatment of AIDS. Green H, et al. Among authors: bacheler lt. Antivir Ther. 2006;11(7):857-67. Antivir Ther. 2006. PMID: 17302248 Clinical Trial.
Resistance and virological response analyses in a three initial treatment strategy trial: a substudy of the INITIO trial.
Descamps D, Chazallon C, Loveday C, Bacheler L, Goodall R, Yéni P, Cooper DA, Babiker A, Aboulker JP, Brun-Vézinet F; Nitio Trial International Coordinating Committee. Descamps D, et al. Among authors: bacheler l. HIV Clin Trials. 2009 Nov-Dec;10(6):385-93. doi: 10.1310/hct1006-385. HIV Clin Trials. 2009. PMID: 20133269 Clinical Trial.
DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants.
Schinazi RF, Mellors J, Bazmi H, Diamond S, Garber S, Gallagher K, Geleziunas R, Klabe R, Pierce M, Rayner M, Wu JT, Zhang H, Hammond J, Bacheler L, Manion DJ, Otto MJ, Stuyver L, Trainor G, Liotta DC, Erickson-Viitanen S. Schinazi RF, et al. Among authors: bacheler l. Antimicrob Agents Chemother. 2002 May;46(5):1394-401. doi: 10.1128/AAC.46.5.1394-1401.2002. Antimicrob Agents Chemother. 2002. PMID: 11959574 Free PMC article.
DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants.
Kaltenbach RF 3rd, Trainor G, Getman D, Harris G, Garber S, Cordova B, Bacheler L, Jeffrey S, Logue K, Cawood P, Klabe R, Diamond S, Davies M, Saye J, Jona J, Erickson-Viitanen S. Kaltenbach RF 3rd, et al. Among authors: bacheler l. Antimicrob Agents Chemother. 2001 Nov;45(11):3021-8. doi: 10.1128/AAC.45.11.3021-3028.2001. Antimicrob Agents Chemother. 2001. PMID: 11600351 Free PMC article.
Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data.
Winters B, Montaner J, Harrigan PR, Gazzard B, Pozniak A, Miller MD, Emery S, van Leth F, Robinson P, Baxter JD, Perez-Elias M, Castor D, Hammer S, Rinehart A, Vermeiren H, Van Craenenbroeck E, Bacheler L. Winters B, et al. Among authors: bacheler l. J Acquir Immune Defic Syndr. 2008 May 1;48(1):26-34. doi: 10.1097/QAI.0b013e31816d9bf4. J Acquir Immune Defic Syndr. 2008. PMID: 18360290
76 results